SILO (silopharma.com) Bathi resik

The financial profit of Silo Pharma, Inc. (SILO) demonstrates capital dynamics, where -0.00 represents the current metric. Silo Pharma, Inc. (SILO) is developing transdermal psilocybin delivery systems to combat neuropsychiatric pathologies. The biopharmaceutical startup utilizes nanotechnology to create targeted treatments for dementia and PTSD. The strategy is based on the synthesis of non-hallucinogenic microdoses, which will allow the company to secure a leading position in modern psychiatry.

Fundamental profit analysis minimizes risks by identifying the actual capacity of Silo Pharma, Inc. (SILO) to fund the development of psychedelic microdosing for the therapy of neurodegenerative pathologies. This metric measures the net remaining funds after deducting all operating expenses; therefore, the company's profit dynamics on this chart serve as an indicator of financial stability and the justification of the company's market capitalization.